Drugs / SBD111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07538167 | Apr 2026 → Jan 2027 expected | osteoporosis | Solarea Bio, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBD111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07538167 ↗ |
| Known as | Bondia | “SBD111 (Bondia), is a commercial medical food for dietary management of postmenopausal bone loss.” NCT07538167 ↗ |
| Modality | Other / unclassified | “SBD111 is a food made of probiotic microbes (bacteria and yeast) and prebiotic dietary fibers” NCT07538167 ↗ |